Kura Oncology, Inc. — Form 8-K
Filed August 12, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 52/100
What the filing says
Kura Oncology reported Q2 2026 net product revenue of $9.1 million (up 57% from Q1 2026), with approximately 115 new patient starts (up 35% QoQ), achieving majority market share in the R/R NPM1-mutant AML menin inhibitor class in only its second full quarter post-launch. The company holds $519.0 million in cash plus $180 million in anticipated Kyowa Kirin collaboration payments, expecting runway through 2028 KOMET-017 Phase 3 topline results. Darlifarnib clinical data across multiple solid tumor indications showed encouraging activity (ORRs ranging 29–67%), supporting potential as a combination platform.
Why this rating
Early commercial traction ($9.1M Q2 revenue is meaningful but small vs $496M market cap). Market leadership claim is encouraging but single-product risk remains; cash runway adequate. Clinical data supportive but still Phase 1. Moderate near-term catalyst value.
See more from August 12, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.